Anti-PD-1 and anti-PD-L1 antibodies, whether alone or combined with chemotherapy or anti-CTLA-4 antibodies, are standard treatments for advanced NSCLC. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.